Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

BACKGROUND: Hyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders. METHODS: In this double-blind, parallel-group, place...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampson, Mark, Faria, Nuno, Powell, Jonathan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311578/
https://www.ncbi.nlm.nih.gov/pubmed/32651955
http://dx.doi.org/10.1093/ndt/gfaa116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311578/
https://www.ncbi.nlm.nih.gov/pubmed/32651955
http://dx.doi.org/10.1093/ndt/gfaa116

Ejemplares similares